tirzepatide dosage increase schedule vs semaglutide chart: complete comparison guide Updated Titration Decision Flowchart: When

modified ITT: 6,586 tirzepatide vs 6,579 dulaglutide Primary MACE-3 events: 12.2% vs 13.1% (HR 0.92

This review explores the complex interplay between hyperkalemia and the use of guideline-directed medical therapies (GDMT), such as reninangiotensinaldosterone system inhibitors (RAASi) and steroidal mineralocorticoid receptor antagonists (sMRAs), including spironolactone and eplerenone, which are currently recommended in guidelines for improving outcomes in heart failure with reduced ejection fraction (HFrEF)

Tirzepatide is a medication that mimics two key hormones involved in blood sugar regulation and appetite control: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)

Tirzepatide is a dual GLP-1/GIP receptor agonist used for weight loss, but some patients wonder if it slows stomach emptying

GLP-1 therapy for appetite control

GLP-1 medication users: those on semaglutide/tirzepatide experiencing slower gastric emptying may benefit from enzyme support (consult physician)